Besifloxacin hydrochloride
- CAS No.
- 405165-61-9
- Chemical Name:
- Besifloxacin hydrochloride
- Synonyms
- CS-781;Pranoprofer;BOL-303224-A;Unii-7506A6J57t;Besifloxacin HC;Besifloxacin HCl;Besivance hydrochloride;Hydrochloric Besifloxacin;7-[(3R)-3-AMinohexahydro-;Becifloxacin Hydrochloride
- CBNumber:
- CB62492988
- Molecular Formula:
- C19H22Cl2FN3O3
- Molecular Weight:
- 430.3
- MDL Number:
- MFCD14636632
- MOL File:
- 405165-61-9.mol
- MSDS File:
- SDS
| Melting point | >210°C (dec.) |
|---|---|
| storage temp. | Inert atmosphere,2-8°C |
| solubility | Methanol (Slightly, Heated, Sonicated), Water (Slightly, Heated, Sonicated) |
| form | Solid |
| color | Off-White to Light Beige |
| FDA UNII | 7506A6J57T |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H315-H319-H335 | |||||||||
| Precautionary statements | P261-P305+P351+P338 | |||||||||
| NFPA 704 |
|
Besifloxacin hydrochloride price More Price(21)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 23692 | Besifloxacin (hydrochloride) ≥95% | 405165-61-9 | 5mg | $44 | 2024-03-01 | Buy |
| Cayman Chemical | 23692 | Besifloxacin (hydrochloride) ≥95% | 405165-61-9 | 10mg | $84 | 2024-03-01 | Buy |
| Cayman Chemical | 23692 | Besifloxacin (hydrochloride) ≥95% | 405165-61-9 | 25mg | $193 | 2024-03-01 | Buy |
| TRC | B319000 | BesifloxacinHydrochloride(Contains~15%Inorganics) | 405165-61-9 | 25mg | $135 | 2021-12-16 | Buy |
| Usbiological | 257222 | Besifloxacin hydrochloride | 405165-61-9 | 250mg | $333 | 2021-12-16 | Buy |
Besifloxacin hydrochloride Chemical Properties,Uses,Production
Outline
Besifloxacin hydrochloride is developed by Bausch & Lomba as a new type of fluoroquinolones for the treatment of bacterial conjunctivitis (a non-viral caused infectious purulent eye irritation conjunctivitis ). Bacterial conjunctivitis which is a contagious eye disease, is a common disease that affects people of all ages. The clinical symptoms of infested eye including: foreign body sensation, burning sensation, tearing; conjunctival hyperemia, mucus or purulent discharge; eyelid edema, conjunctival edema and subconjunctival hemorrhage may occur in severe cases .
Besifloxacin hydrochloride ophthalmic suspension
Besifloxacin hydrochloride ophthalmic suspension (Besivance) is a fluoroquinolone drug recently approved for the topical treatment of bacterial conjunctivitis. This medicine can quickly kill common pathogens causing conjunctivitis , that is coagulase-negative staphylococci, Streptococcus pneumoniae, Staphylococcus aureus , Haemophilus influenzae bacteria, and other less common bacteria.. Besifloxacin is an effective drug to the Gram-positive and Gram-negative pathogens, include other fluoroquinolone-resistant bacteria , also it can balance the DNA gyrase and topoisomerase IV activity, slow the development of resistance. Topical administration can achieve stable and lasting high concentrations in human tears , and penetration in animal ocular tissue is good, showing excellent safety.
Pharmacokinetic and pharmacodynamic characteristics of Besifloxacin meet the criteria for successfully clearing most Gram-positive and Gram-negative bacteria, while exhibiting minimal systemic exposure.Besifloxacin biochemical properties, pharmacokinetics targeted to achieve/pharmacodynamic objectives and limited to local ophthalmic drug will slow the development of bacterial resistance, making Besifloxacin become attractive choice for acute bacterial conjunctivitis treatment.
The above information is edited by the chemicalbook of Tian Ye.
Description
Besifloxacin is a new fluoroquinolone antibacterial for ophthalmic use. It is indicated for the treatment of bacterial conjunctivitis, one of the most common ocular infections encountered in the primary care setting. Although the previously marketed fluoroquinolones ciprofloxacin, levofloxacin, ofloxacin, gatifloxacin, and moxifloxacin have been widely used to treat bacterial conjunctivitis, their continued utility is hampered by the emergence of resistance among key ocular isolates such as Staphylococcus aureus. Besifloxacin is the first fluoroquinolone developed exclusively for topical ophthalmic use. Unlike the previously marketed fluoroquinolones, besifloxacin has not been used systemically and is not in development as a systemic agent. Its exclusive indication as a topical agent is expected to reduce the overall environmental exposure of bacteria to besifloxacin, which may contribute to a lower risk for the emergence of bacterial resistance. Fluoroquinolones derive their antibacterial activity via inhibition of two essential bacterial enzymes, DNA gyrase and topoisomerase IV, which regulate processes of DNA replication. Besifloxacin inhibits DNA gyrase and topoisomerase IV from Streptococcus pneumoniae (IC50 = 1 and 0.4 mg/ L, respectively) and Escherichia coli (IC50 = 1 and 10 mg/L, respectively).
Chemical Properties
Pale Yellow Solid
Originator
SSP Co. Ltd. (Japan) (Japan)
Uses
A Fluoroquinolone antibiotic.
Uses
Besifloxacin HCl is a fourth-generation fluoroquinolone antibiotic
brand name
Besivance
Side effects
The most common adverse event reported in patients treated with besifloxacin ophthalmic suspension was conjunctival redness. Other less common adverse events were blurred vision, eye pain, eye irritation, eye pruritus, and headache.
Synthesis
Besifloxacin is a fourth-generation fluoroquinolone antibiotic which is marketed as besifloxacin hydrochloride. It was originally developed by the Japanese firm SSP Co. Ltd and designated SS734. SSP then licensed U.S. and European rights of SS734 for ophthalmic use to InSite Vision, Inc., in 2000, who then developed an eye drop formulation (ISV-403) and conducted preliminary clinical trials before selling the product and all rights to Bausch & Lomb in 2003. The eye drop was approved by the United States Food and Drug Administration (FDA) on May 29, 2009 and marketed under the trade name Besivance. Besifloxacin has been found to inhibit production of pro-inflammatory cytokines in vitro. The synthesis of besifloxacin commences with commercially available ethyl 3-(3-chloro-2,4,5-trifluorophenyl)-3-oxopropanoate.Condensation of this ketoester with triethyl orthoformate resulted in a mixture of vinylogous esters 14. Substitution with cyclopropanamine converts 14 to the vinylogous amide 15 as an unreported distribution of cis- and trans-isomers. This mixture was treated with base at elevated temperature to give 16. Presumably, the trans-isomer isomerizes to the cis-isomer, which subsequently undergoes an intramolecular nucleophilic aromatic substitution with concomitant saponification to construct quinolone acid 16. Quinolone 16 is then subjected to another nucleophilic substitution involving readily available iminoazepine 17 and the displacement reaction proceeds regioselectively to furnish the atomic framework of besifloxacin (18). Acidic methanolysis of 18 at elevated temperature gave besiflozacin (III).
Besifloxacin hydrochloride Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Nanjing Kaitian Chemical Co., LTD | +undefined13337835376 | kt_chem@126.com | China | 40 | 58 |
| Hebei Chuanghai Biotechnology Co,.LTD | +86-13131129325 | sales1@chuanghaibio.com | China | 5892 | 58 |
| BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 +86-18600796368 | sales@sjar-tech.com | China | 444 | 58 |
| Capot Chemical Co.,Ltd. | +86-（0）57185586718 +86-13336195806 | sales@capot.com | China | 29791 | 60 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21634 | 55 |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32957 | 60 |
| Hefei TNJ Chemical Industry Co.,Ltd. | +86-0551-65418679 +8618949832763 | info@tnjchem.com | China | 2986 | 55 |
| career henan chemical co | +86-0371-86658258 +8613203830695 | sales@coreychem.com | China | 29881 | 58 |
| Zhejiang ZETian Fine Chemicals Co. LTD | +8618957127338 | stella@zetchem.com | China | 2136 | 58 |
| Jinan Shengqi pharmaceutical Co,Ltd | 86+18663751872 | christine@shengqipharm.com | CHINA | 491 | 58 |
View Lastest Price from Besifloxacin hydrochloride manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-11-27 | Besifloxacin Hcl Intermediate
405165-61-9
|
US $0.00 / Kg/Drum | 1KG | 99% | 500kg | WUHAN FORTUNA CHEMICAL CO., LTD | |
 |
2024-11-19 | Besifloxacin Hydrochloride
405165-61-9
|
US $32.00-98.00 / mg | 99.95% | 10g | TargetMol Chemicals Inc. | ||
 |
2024-11-18 | Besifloxacin Hydrochloride
405165-61-9
|
US $0.00 / g | 1g | More Than 99% | 100kg/Month | BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. |
-
- Besifloxacin Hcl Intermediate
405165-61-9
- US $0.00 / Kg/Drum
- 99%
- WUHAN FORTUNA CHEMICAL CO., LTD
-
- Besifloxacin Hydrochloride
405165-61-9
- US $32.00-98.00 / mg
- 99.95%
- TargetMol Chemicals Inc.
-
- Besifloxacin Hydrochloride
405165-61-9
- US $0.00 / g
- More Than 99%
- BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.